This Article  • Full text  • PDF  • Video  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (774)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Steven E. Nissen, MD; E. Murat Tuzcu, MD; Paul Schoenhagen, MD; B. Greg Brown, MD; Peter Ganz, MD; Robert A. Vogel, MD; Tim Crowe, BS; Gail Howard, MS; Christopher J. Cooper, MD; Bruce Brodie, MD; Cindy L. Grines, MD; Anthony N. DeMaria, MD; for the REVERSAL Investigators

JAMA. 2004;291:1071-1080.

Context  Statin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality. However, the optimal strategy and target level for lipid reduction remain uncertain.

Objective  To compare the effect of regimens designed to produce intensive lipid lowering or moderate lipid lowering on coronary artery atheroma burden and progression.

Design, Setting, and Patients  Double-blind, randomized active control multicenter trial (Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL]) performed at 34 community and tertiary care centers in the United States comparing the effects of 2 different statins administered for 18 months. Intravascular ultrasound was used to measure progression of atherosclerosis. Between June 1999 and September 2001, 654 patients were randomized and received study drug; 502 had evaluable intravascular ultrasound examinations at baseline and after 18 months of treatment.

Interventions  Patients were randomly assigned to receive a moderate lipid-lowering regimen consisting of 40 mg of pravastatin or an intensive lipid-lowering regimen consisting of 80 mg of atorvastatin.

Main Outcome Measures  The primary efficacy parameter was the percentage change in atheroma volume (follow-up minus baseline).

Results  Baseline low-density lipoprotein cholesterol level (mean, 150.2 mg/dL [3.89 mmol/L] in both treatment groups) was reduced to 110 mg/dL (2.85 mmol/L) in the pravastatin group and to 79 mg/dL (2.05 mmol/L) in the atorvastatin group (P<.001). C-reactive protein decreased 5.2% with pravastatin and 36.4% with atorvastatin (P<.001). The primary end point (percentage change in atheroma volume) showed a significantly lower progression rate in the atorvastatin (intensive) group (P = .02). Similar differences between groups were observed for secondary efficacy parameters, including change in total atheroma volume (P = .02), change in percentage atheroma volume (P<.001), and change in atheroma volume in the most severely diseased 10-mm vessel subsegment (P<.01). For the primary end point, progression of coronary atherosclerosis occurred in the pravastatin group (2.7%; 95% confidence interval [CI], 0.2% to 4.7%; P = .001) compared with baseline. Progression did not occur in the atorvastatin group (–0.4%; CI –2.4% to 1.5%; P = .98) compared with baseline.

Conclusions  For patients with coronary heart disease, intensive lipid-lowering treatment with atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin. Compared with baseline values, patients treated with atorvastatin had no change in atheroma burden, whereas patients treated with pravastatin showed progression of coronary atherosclerosis. These differences may be related to the greater reduction in atherogenic lipoproteins and C- reactive protein in patients treated with atorvastatin.

Author Affiliations: Departments of Cardiovascular Medicine (Drs Nissen, Tuzcu, Schoenhagen, and Mr Crowe) and Diagnostic Radiology (Dr Schoenhagen), Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio; Department of Medicine, University of Washington, Seattle (Dr Brown); Department of Medicine, Brigham and Women's Hospital, Boston, Mass (Dr Ganz); Department of Medicine, University of Maryland, Baltimore (Dr Vogel); Pfizer Inc, New York, NY (Ms Howard); Department of Medicine, Medical College of Ohio, Toledo (Dr Cooper); LeBauer Cardiovascular Research Foundation, Greensboro, NC (Dr Brodie); Cardiac Catheterization Laboratory, Division of Cardiac Diseases, William Beaumont Hospital, Royal Oak, Mich (Dr Grines); and Department of Medicine, University of California, San Diego (Dr DeMaria).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Uffe Ravnskov and Morley C. Sutter
JAMA. 2004;292(1):38.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Paul J. Rosch
JAMA. 2004;292(1):38-39.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Kavitha Rajaram
JAMA. 2004;292(1):39.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
Pim van der Harst, Wiek H. van Gilst, and Felix Zijlstra
JAMA. 2004;292(1):39.
EXTRACT | FULL TEXT  

Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma—Reply
Steven Nissen and For the REVERSAL Investigators
JAMA. 2004;292(1):39-40.
EXTRACT | FULL TEXT  

RELATED ARTICLE

High-Intensity Statin Treatment for Coronary Heart Disease
Frank M. Sacks
JAMA. 2004;291(9):1132-1134.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.
Hata et al.
Ann. Thorac. Surg. 2009;88:1440-1444.
ABSTRACT | FULL TEXT  

American Diabetes Association Indications for Statins in Diabetes: Is there evidence?
Eldor and Raz
Diabetes Care 2009;32:S384-S391.
FULL TEXT  

ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease.
American College of Cardiology Foundation et al.
J Am Coll Cardiol 2009;54:1336-1363.
FULL TEXT  

ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association
WRITING COMMITTEE MEMBERS et al.
Circulation 2009;120:e100-e126.
FULL TEXT  

Atherosclerotic Plaque Progression in Carotid Arteries: Monitoring with High-Spatial-Resolution MR Imaging--Multicenter Trial
Boussel et al.
Radiology 2009;252:789-796.
ABSTRACT | FULL TEXT  

Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O'Keefe et al.
Mayo Clin Proc. 2009;84:741-757.
ABSTRACT | FULL TEXT  

Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study).
Hiro et al.
J Am Coll Cardiol 2009;54:293-302.
ABSTRACT | FULL TEXT  

Association between statin-associated myopathy and skeletal muscle damage
Mohaupt et al.
CMAJ 2009;181:E11-E18.
ABSTRACT | FULL TEXT  

A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study
Luscher et al.
Eur Heart J 2009;30:1590-1597.
ABSTRACT | FULL TEXT  

Structural and functional manifestations of human atherosclerosis: do they run in parallel?
Ganz et al.
Eur Heart J 2009;30:1556-1558.
FULL TEXT  

Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis
Hong et al.
J Am Coll Cardiol Intv 2009;2:679-688.
ABSTRACT | FULL TEXT  

Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound
Nasu et al.
J Am Coll Cardiol Intv 2009;2:689-696.
ABSTRACT | FULL TEXT  

Can Statins Alter Coronary Plaque Composition Assessed by Radiofrequency Backscatter Intravascular Ultrasound?
Samady and McDaniel
J Am Coll Cardiol Intv 2009;2:697-700.
FULL TEXT  

Statins for all: the new premed?
Brookes et al.
Br J Anaesth 2009;103:99-107.
ABSTRACT | FULL TEXT  

The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Meaney et al.
J Clin Pharmacol 2009;49:838-847.
ABSTRACT | FULL TEXT  

Positive remodeling of the coronary arteries detected by magnetic resonance imaging in an asymptomatic population: MESA (Multi-Ethnic Study of Atherosclerosis).
Miao et al.
J Am Coll Cardiol 2009;53:1708-1715.
ABSTRACT | FULL TEXT  

Disease progression in nonintervened saphenous vein graft segments a serial intravascular ultrasound analysis.
Hong et al.
J Am Coll Cardiol 2009;53:1257-1264.
ABSTRACT | FULL TEXT  

Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
Chhatriwalla et al.
J Am Coll Cardiol 2009;53:1110-1115.
ABSTRACT | FULL TEXT  

Carotid Intima-Media Thickness and Coronary Artery Calcium Score as Indications of Subclinical Atherosclerosis
Lester et al.
Mayo Clin Proc. 2009;84:229-233.
ABSTRACT | FULL TEXT  

Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins
Sassano et al.
Molecular Cancer Therapeutics 2009;8:615-625.
ABSTRACT | FULL TEXT  

Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy
Fitzgerald et al.
Vasc Med 2009;14:21-27.
ABSTRACT  

JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
SHISHEHBOR and HAZEN
Cleveland Clinic Journal of Medicine 2009;76:37-44.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT  

Diabetics on dialysis in Italy: a nationwide epidemiological study
Panzetta et al.
Nephrol Dial Transplant 2008;23:3988-3995.
ABSTRACT | FULL TEXT  

Statins: established indications and controversial subgroups
Jukema and Bergheanu
Heart 2008;94:1656-1662.
FULL TEXT  

Treatment of Diabetes in Long-Term Care Facilities: A Primary Care Approach
Johnson et al.
Clin. Diabetes 2008;26:152-156.
ABSTRACT | FULL TEXT  

Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque
Serruys et al.
Circulation 2008;118:1172-1182.
ABSTRACT | FULL TEXT  

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)
Newman et al.
Diabetes and Vascular Disease Research 2008;5:177-183.
ABSTRACT  

Unraveling Pleiotropic Effects Of Statins: Bit By Bit, a Slow Case With Perspective
Arslan et al.
Circ. Res. 2008;103:334-336.
FULL TEXT  

Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg et al.
Circulation 2008;118:672-677.
FULL TEXT  

Intensive Lipid Intervention in the Post-ENHANCE Era
O'Keefe et al.
Mayo Clin Proc. 2008;83:867-869.
FULL TEXT  

Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling: A Pooled Analysis of 5 Intravascular Ultrasound Trials
Nicholls et al.
J Am Coll Cardiol 2008;52:255-262.
ABSTRACT | FULL TEXT  

Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma
Woodard et al.
Clin. Cancer Res. 2008;14:4640-4649.
ABSTRACT | FULL TEXT  

Vascular form and function: two mechanisms for cardiovascular prevention
Kinlay
Eur Heart J 2008;29:1711-1713.
FULL TEXT  

Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume Observations From the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) Study.
Choi et al.
J Am Coll Cardiol 2008;52:24-32.
ABSTRACT | FULL TEXT  

Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy
Bhavnani et al.
Europace 2008;10:854-859.
ABSTRACT | FULL TEXT  

Overview of clinical trials on calcific aortic stenosis
Pedersen
Eur Heart J Suppl 2008;10:E31-E40.
ABSTRACT | FULL TEXT  

Impact of Plasma Oxidized Low-Density Lipoprotein Removal on Atherosclerosis
Ishigaki et al.
Circulation 2008;118:75-83.
ABSTRACT | FULL TEXT  

Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis
Han et al.
Eur Heart J 2008;29:1359-1369.
ABSTRACT | FULL TEXT  

Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden
Ballantyne et al.
Circulation 2008;117:2458-2466.
ABSTRACT | FULL TEXT  

Do the extent and direction of arterial remodelling predict subsequent progression of coronary atherosclerosis? A serial intravascular ultrasound study
Sipahi et al.
Heart 2008;94:623-627.
ABSTRACT | FULL TEXT  

The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans
Ky et al.
J Am Coll Cardiol 2008;51:1653-1662.
ABSTRACT | FULL TEXT  

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial
Nissen et al.
JAMA 2008;299:1561-1573.
ABSTRACT | FULL TEXT  

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease: The STRADIVARIUS Randomized Controlled Trial
Nissen et al.
JAMA 2008;299:1547-1560.
ABSTRACT | FULL TEXT  

Ultrasound imaging techniques for the evaluation of cardiovascular therapies
Kastelein and de Groot
Eur Heart J 2008;29:849-858.
ABSTRACT | FULL TEXT  

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis.
Ibanez et al.
J Am Coll Cardiol 2008;51:1104-1109.
ABSTRACT | FULL TEXT  

Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy
Sabatine et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:562-567.
ABSTRACT | FULL TEXT  

Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona
Mayo Clin Proc. 2008;83:333-342.
ABSTRACT | FULL TEXT  

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Josan et al.
CMAJ 2008;178:576-584.
ABSTRACT | FULL TEXT  

Lower extremity vein graft failure: a translational approach
Owens et al.
Vasc Med 2008;13:63-74.
ABSTRACT  

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Risk factor status and vascular events in patients with symptomatic intracranial stenosis
Chaturvedi et al.
Neurology 2007;69:2063-2068.
ABSTRACT | FULL TEXT  

Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data
Issac et al.
J Am Coll Cardiol 2007;50:2021-2028.
ABSTRACT | FULL TEXT  

Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
Mudd et al.
J Am Coll Cardiol 2007;50:1735-1741.
ABSTRACT | FULL TEXT  

Impact of C-reactive protein on treatment of patients with cardiovascular disease
Gortney and Sanders
Am J Health Syst Pharm 2007;64:2009-2016.
ABSTRACT | FULL TEXT  

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Authors/Task Force Members et al.
Eur Heart J 2007;28:2375-2414.
FULL TEXT  

Assessment of Culprit Lesion Morphology in Acute Myocardial Infarction: Ability of Optical Coherence Tomography Compared With Intravascular Ultrasound and Coronary Angioscopy
Kubo et al.
J Am Coll Cardiol 2007;50:933-939.
ABSTRACT | FULL TEXT  

Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin
Laudi et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2007;293:L630-L638.
ABSTRACT | FULL TEXT  

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Afilalo et al.
Heart 2007;93:914-921.
ABSTRACT | FULL TEXT  

Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease
Yu et al.
Heart 2007;93:933-939.
ABSTRACT | FULL TEXT  

How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials
Schedlbauer et al.
Fam Pract 2007;24:380-387.
ABSTRACT | FULL TEXT  

{beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials
Sipahi et al.
ANN INTERN MED 2007;147:10-18.
ABSTRACT | FULL TEXT  

Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus
Raggi and Bellasi
British Journal of Diabetes & Vascular Disease 2007;7:157-164.
ABSTRACT  

Plaque Temperature, Arterial Remodeling, and Inflammation: Understanding "Hot-Spots" in the Coronary Arteries
Schoenhagen
J Am Coll Cardiol 2007;49:2272-2273.
FULL TEXT  

The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Windler et al.
Diabetes and Vascular Disease Research 2007;4:136-142.
ABSTRACT  

Intravascular ultrasound radiofrequency analysis of coronary atherosclerosis: an emerging technology for the assessment of vulnerable plaque
Mehta et al.
Eur Heart J 2007;28:1283-1288.
ABSTRACT | FULL TEXT  

Type 2 diabetes patients: profiles, treatment and daily practice
Zambon
Diabetes and Vascular Disease Research 2007;4:S12-S16.
 

Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis
Kinlay
J Am Coll Cardiol 2007;49:2003-2009.
ABSTRACT | FULL TEXT  

Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets
Lee and Choudhury
Heart 2007;93:559-564.
ABSTRACT | FULL TEXT  

Endothelial Mitochondria: Contributing to Vascular Function and Disease
Davidson and Duchen
Circ. Res. 2007;100:1128-1141.
ABSTRACT | FULL TEXT  

Rate of Progression of Coronary Atherosclerotic Plaque in Women
Nicholls et al.
J Am Coll Cardiol 2007;49:1546-1551.
ABSTRACT | FULL TEXT  

A Direct Comparison of Intravascular Ultrasound and Quantitative Coronary Arteriography: Implications for Measures of Atherosclerosis as Clinical Surrogates
Brown
Circulation 2007;115:1824-1826.
FULL TEXT  

Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population
Song et al.
Am J Health Syst Pharm 2007;64:767-772.
ABSTRACT | FULL TEXT  

Post-Cardiothoracic Surgery Atrial Fibrillation: A Review of Preventive Strategies
Baker and White
The Annals of Pharmacotherapy 2007;41:587-598.
ABSTRACT | FULL TEXT  

Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen et al.
NEJM 2007;356:1304-1316.
ABSTRACT | FULL TEXT  

Impact of Metabolic Syndrome on Tissue Characteristics of Angiographically Mild to Moderate Coronary Lesions: Integrated Backscatter Intravascular Ultrasound Study
Amano et al.
J Am Coll Cardiol 2007;49:1149-1156.
ABSTRACT | FULL TEXT  

Is Intravascular Ultrasound the Gold Standard Surrogate for Clinically Relevant Atherosclerosis Progression?
Brown and Zhao
J Am Coll Cardiol 2007;49:933-938.
ABSTRACT | FULL TEXT